Suzhou Dongrui Pharmaceutical

Suzhou Dongrui Pharmaceutical is a leading Chinese pharmaceutical manufacturer specializing in the development and production of cephalosporin antibiotics and systemic specialty drugs. The company has established an advanced technology platform for third-generation cephalosporin synthesis with international-level product quality. It supplies both domestic and international markets with raw materials, intermediates, powder injections, tablets, capsules, and granules. The company also invests heavily in R&D for synthetic specialty drug analogs ("imitation anthers") as well as some innovative compounds. In 2024 it transferred the license for rosuvastatin calcium tablets to Shandong Xinhua Pharmaceutical.